Ascentage Pharma Group International (FRA:36X) Total Liabilities : €298.4 Mil (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International Total Liabilities?

Ascentage Pharma Group International's Total Liabilities for the quarter that ended in Jun. 2024 was €298.4 Mil.

Ascentage Pharma Group International's quarterly Total Liabilities increased from Jun. 2023 (€298.74 Mil) to Dec. 2023 (€312.05 Mil) but then declined from Dec. 2023 (€312.05 Mil) to Jun. 2024 (€298.45 Mil).

Ascentage Pharma Group International's annual Total Liabilities increased from Dec. 2021 (€236.95 Mil) to Dec. 2022 (€327.90 Mil) but then declined from Dec. 2022 (€327.90 Mil) to Dec. 2023 (€312.05 Mil).

Ascentage Pharma Group International Total Liabilities Historical Data

The historical data trend for Ascentage Pharma Group International's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International Total Liabilities Chart

Ascentage Pharma Group International Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

40.37

111.17

236.95

327.90

312.05

Ascentage Pharma Group International Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Liabilities	Get a 7-Day Free Trial										304.92	327.90	298.74	312.05	298.45

Ascentage Pharma Group International Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ascentage Pharma Group International's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	119.974	+	(151.441	+	38.284
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	2.35)
	=	312.0

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	321.12	-	9.071
	=	312.0

Ascentage Pharma Group International's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	136.423	+	(124.284	+	35.334
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	2.35)
	=	298.4

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	397.876	-	99.427
	=	298.4

Ascentage Pharma Group International Total Liabilities Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascentage Pharma Group International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (FRA:36X) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

AAPG:USA ASPHF:USA 06855:Hong Kong 36X:Germany

Address

68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000

Website

https://www.ascentagepharma.com

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company's geographical segments include the United States and Mainland China.

Ascentage Pharma Group International Headlines

No Headlines